A Phase 2a clinical trial of Molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus

Authors
Publication date
1 January 2021
Publisher
Doi

    Abstract

    Molnupiravir (800 mg dose) accelerated SARS-CoV-2 RNA clearance in patients with COVID-19 compared to placebo

      Similar works

      Full text

      thumbnail-image

      Available Versions

      Carolina Digital Repository

      redirect
      oaicdr.lib.unc.edu:j6731d15c
      Last time updated on 09/06/2022